Stephanie K. Dougan, PhD
A cancer immunologist asking the hardest question in the field: why pancreatic tumors resist immunotherapy, and how to break that resistance.
Overview
Dr. Stephanie Dougan is a cancer immunologist whose laboratory investigates why pancreatic cancer resists immunotherapy and how to overcome that barrier. She holds joint appointments at Harvard Medical School and Dana-Farber Cancer Institute, and is an investigator at the Hale Family Center for Pancreatic Cancer Research.
Research focus
Most pancreatic tumors fail to recruit CD8+ T cells, which is what renders checkpoint blockade ineffective. Her lab asks how to prime and reprogram the tumor microenvironment to change that — using transnuclear and CRISPR-engineered mouse systems to dissect anti-tumor immunity, and samples from immunotherapy clinical trials to understand how the immune system meets pancreatic cancer in actual patients.
Training
PhD in Immunology from Harvard, working on lipid antigen presentation and CD1d/NKT biology, followed by a postdoctoral fellowship at the Whitehead Institute with Hidde Ploegh building engineered mouse models. She joined the Harvard Medical School and Dana-Farber faculty in 2014.
Nine physicians, researchers and staff who decide what Sky funds.
Back to the SAC →Stephanie K. Dougan, PhD
A cancer immunologist asking the hardest question in the field: why pancreatic tumors resist immunotherapy, and how to break that resistance.
Overview
Dr. Stephanie Dougan is a cancer immunologist whose laboratory investigates why pancreatic cancer resists immunotherapy and how to overcome that barrier. She holds joint appointments at Harvard Medical School and Dana-Farber Cancer Institute, and is an investigator at the Hale Family Center for Pancreatic Cancer Research.
Research focus
Most pancreatic tumors fail to recruit CD8+ T cells, which is what renders checkpoint blockade ineffective. Her lab asks how to prime and reprogram the tumor microenvironment to change that — using transnuclear and CRISPR-engineered mouse systems to dissect anti-tumor immunity, and samples from immunotherapy clinical trials to understand how the immune system meets pancreatic cancer in actual patients.
Training
PhD in Immunology from Harvard, working on lipid antigen presentation and CD1d/NKT biology, followed by a postdoctoral fellowship at the Whitehead Institute with Hidde Ploegh building engineered mouse models. She joined the Harvard Medical School and Dana-Farber faculty in 2014.
Nine physicians, researchers and staff who decide what Sky funds.
Back to the SAC →